Oxford Expression Technologies Limited
Registered name: OXFORD EXPRESSION TECHNOLOGIES LIMITED
Oxford Expression Technologies Limited made £477k profit in the year to 31 Oct 2025 (revenue not disclosed).
Oxford Expression Technologies Limited reported £477k profit in the year to 31 Oct 2025, down 34% on the year before; its revenue was not disclosed. It had 15 employees. The company is classified under “research and experimental development on biotechnology” and is based in Newbury; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Newbury, South East
- Age
- 20 yrs · since 2006
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The Company is under the control of its directors.”
Key figures
This company published its profit but not its turnover, so revenue and margins are not disclosed. We never estimate them.
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Oct 2022 | 31 Oct 2023 | 31 Oct 2024 | 31 Oct 2025 |
|---|---|---|---|---|
| Disclosure | Profit only | Profit only | Profit only | Profit only |
| Profit & loss | ||||
| Revenue (turnover) | — | — | — | — |
| Profit after tax | £437k | £210k | £718k | £477k |
| Profit (best available) | £437k | £210k | £718k | £477k |
| Employees (average) | 15 | 16 | 18 | 15 |
| Ratios | ||||
| Profit margin | — | — | — | — |
| Profit per employee | £29.1k | £13.1k | £39.9k | £31.8k |
| Growth (year on year) | ||||
| Profit growth | — | ▼51.9% | ▲241.6% | ▼33.5% |
| Headcount growth | — | ▲6.7% | ▲12.5% | ▼16.7% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £1.8m | £1.8m | £2m | £1.7m |
| Net assets | £2m | £2m | £2.6m | £2.8m |
| Fixed assets | £93.4k | £121k | £113k | £840k |
| Current assets | £2.1m | £2m | £2.8m | £2.2m |
| Debtors | £180k | £129k | £659k | £224k |
| Source | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Apr 2025 | FullAccounts · bulk data Apr 2026 |
How the business works
- Profit margin
- —
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- —
- Revenue ÷ average employees.
- Profit per employee
- £31.8k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▲6%
- Now £2.8m
- Cash at bank
- ▼15%
- Now £1.7m
- Headcount
- ▼17%
- Now 15
- Deferred income
- —
- Now —
- Fixed assets
- ▲643%
- Now £840k
Group structure
Subsidiaries (1)
- Oet LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 Oct 2025 (profit £477k), from the Companies House accounts bulk data published Apr 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.